文献速递血液净化与透析水电解质与酸碱

血清钠与腹膜透析相关腹膜炎及死亡风险的关联:PDOPPS研究

Associations Between Serum Sodium, Peritoneal Dialysis-Associated Peritonitis, and Mortality in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).
PubMed 文献 · Am J Kidney Dis · 2025-04-10

基于8国23,707例腹膜透析患者的观察性队列,评估入组时血清钠水平与首次腹膜炎及全因死亡的关系。与血钠140-141 mEq/L相比,血钠<135、135-137和≥142 mEq/L均与更高的死亡风险相关,而各血钠组腹膜炎风险无差异。

要点

  • 血钠<135 mEq/L者较140-141 mEq/L者死亡风险更高(AHR 1.45,95%CI 1.29-1.63)。
  • 血钠135-137和≥142 mEq/L也分别与更高死亡风险相关,AHR为1.26和1.16。
  • 各血清钠分组之间调整后的腹膜炎风险无差异。

核心结论

  • 血清钠水平波动与死亡相关,但与腹膜炎风险无关。
  • 未来研究需理解这些关联的机制以及纠正血清钠能否改善腹膜透析患者结局。

研究设计与样本

  • 多中心观察性队列研究,纳入2014至2022年8个国家PDOPPS中23,707例入组时有血清钠检测的腹膜透析患者。
  • 暴露为入组时血清钠分组(<135、135-137、138-139、140-141、≥142 mEq/L)。
  • 结局为首次腹膜炎时间和全因死亡,采用病因特异性风险模型调整人口学、合并症和治疗特征。

主要发现

  • 与血钠140-141 mEq/L(n=5,065)相比,血钠<135 mEq/L(n=3,601)者透析龄更长、更可能患糖尿病和使用艾考糊精。
  • 各血清钠分组间调整后腹膜炎风险无差异。
  • 与血钠140-141 mEq/L相比,血钠<135 mEq/L(AHR 1.45,95%CI 1.29-1.63)、135-137 mEq/L(AHR 1.26,95%CI 1.13-1.42)和≥142 mEq/L(AHR 1.16,95%CI 1.03-1.30)均与更高死亡风险相关。
  • 血清钠与死亡的关联在所有患者特征和腹膜透析模式亚组中相似。
  • 无论是否使用艾考糊精,各血清钠分组间腹膜炎风险均未检测到差异。

关键数值与推荐

  • 血钠<135 mEq/L vs 140-141 mEq/L:AHR 1.45(95%CI 1.29-1.63)。
  • 血钠135-137 mEq/L vs 140-141 mEq/L:AHR 1.26(95%CI 1.13-1.42)。
  • 血钠≥142 mEq/L vs 140-141 mEq/L:AHR 1.16(95%CI 1.03-1.30)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 各中心间血清钠检测缺乏标准化和验证。
  • 艾考糊精使用仅限部分患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The clinical consequences of hyponatremia among patients receiving peritoneal dialysis (PD) are poorly understood. This study sought to evaluate the association of variations in serum sodium with peritoneal dialysis-associated peritonitis and death. STUDY DESIGN: Multicenter observational cohort study. SETTINGS & PARTICIPANTS: 23,707 participants in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) in 8 countries between 2014 and 2022 with a serum sodium measure available at study enrollment. PREDICTOR: Serum sodium categories (<135, 135-137, 138-139, 140-141, ≥142 mEq/L) at study enrollment. OUTCOME: Time to first peritonitis episode and all-cause mortality. ANALYTICAL APPROACH: Cause-specific hazards models adjusted for demographic, comorbidity, and treatment characteristics. Secondary analyses using average serum sodium levels over time and evaluation of modification of the association between serum sodium and study outcomes by use of icodextrin as well as patient characteristics and PD modality. RESULTS: Compared to a serum sodium of 140-141 mEq/L (n=5,065), those with a sodium of<135 mEq/L (n=3,601) had longer dialysis vintage and were more likely to have diabetes and use icodextrin. Across serum sodium categories, there were no differences in the adjusted peritonitis risks. Compared to individuals with a sodium of 140-141 mEq/L, those with a sodium of<135 mEq/L (adjusted hazard ratio [AHR], 1.45 [95% CI, 1.29-1.63]), a sodium of 135-137 mEq/L (AHR, 1.26 [95% CI, 1.13-1.42]), and a sodium≥142 mEq/L (AHR, 1.16 [95% CI, 1.03-1.30]) were all associated with higher mortality. Associations between serum sodium and mortality were similar across all patient characteristic and PD modality subgroups. Peritonitis risk was not detectably different across serum sodium categories regardless of treatment with icodextrin. LIMITATIONS: Lack of standardization/validation of serum sodium measures across sites; icodextrin use was limited to a subset of patients. CONCLUSIONS: Variations in serum sodium were associated with death but not peritonitis risk. Future studies are needed to understand the mechanisms underpinning these associations and whether modification of serum sodium would improve outcomes among those receiving PD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Teitelbaum I, Zhao J, Tu C, et al. Associations Between Serum Sodium, Peritoneal Dialysis-Associated Peritonitis, and Mortality in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis. 2025. PMID: 40220849. doi:10.1053/j.ajkd.2025.02.605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。